|
|
epratuzumab A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonyms: | | AMG 412 Humanized Anti-CD22 Monoclonal Antibody IgG1 LL2 monoclonal antibody LL2 | | | US brand name: | | LymphoCide | | | Abbreviations: | | hLL2 MOAB LL2 | | |
|
|